This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Moore, Y.E., Kelley, M.R., Brandon, N.J., Deeb, T.Z. & Moss, S.J. Trends Neurosci. 40, 555–571 (2017).
Gagnon, M. et al. Nat. Med. 19, 1524–1528 (2013).
Delpire, E. et al. Bioorg. Med. Chem. Lett. 22, 4532–4535 (2012).
Rouzaire-Dubois, B., Bostel, S. & Dubois, J.M. Neuroscience 88, 307–317 (1999).
Rowe, S.M. & Verkman, A.S. Cold Spring Harb. Perspect. Med. 3, a009761 (2013).
Williams, J.R., Sharp, J.W., Kumari, V.G., Wilson, M. & Payne, J.A. J. Biol. Chem. 274, 12656–12664 (1999).
Zhang, D., Gopalakrishnan, S.M., Freiberg, G. & Surowy, C.S. J. Biomol. Screen. 15, 177–184 (2010).
Payne, J.A. Am. J. Physiol. 273, C1516–C1525 (1997).
Delpire, E. et al. Proc. Natl. Acad. Sci. USA 106, 5383–5388 (2009).
Friedel, P. et al. Sci. Signal. 8, ra65 (2015).
Bornhop, D.J. et al. Science 317, 1732–1736 (2007).
Hamidi, S. & Avoli, M. Neurobiol. Dis. 79, 51–58 (2015).
Ostroumov, A. et al. Neuron 92, 493–504 (2016).
Ferando, I., Faas, G.C. & Mody, I. Nat. Neurosci. 19, 1197–1200 (2016).
Ferrini, F., Lorenzo, L.E., Godin, A.G., Quang, M.L. & De Koninck, Y. Sci. Rep. 7, 3870 (2017).
Friedel, P., Bregestovski, P. & Medina, I. Front. Mol. Neurosci. 6, 7 (2013).
Deeb, T.Z., Nakamura, Y., Frost, G.D., Davies, P.A. & Moss, S.J. Eur. J. Neurosci. 38, 2453–2467 (2013).
Pellegrino, C. et al. J. Physiol. (Lond.) 589, 2475–2496 (2011).
Sivakumaran, S. et al. J. Neurosci. 35, 8291–8296 (2015).
Grimley, J.S. et al. J. Neurosci. 33, 16297–16309 (2013).
We would like to thank S. Geschwindner for critical comments and discussion on the manuscript. We would like to thank G.J. Augustine (Korea Institute of Science and Technology) for generously providing the SuperClomeleon construct. This work was supported by funding from AstraZeneca, a grant from the Simons Foundation (206026 to S.J.M.), NIH–NINDS grants NS051195, NS056359, NS081735, and NS087662 (S.J.M.), and NIH–NIMH MH097446 (P.A.D.).
K.J., L.J.M., P.M.S., M.P.B., D.J.B., N.D., R.J.M., S.Z., Q.W., J.H., M.E.D., J.D., and N.J.B. are or were full-time employees and shareholders of AstraZeneca. S.J.M. serves as a consultant for SAGE therapeutics and AstraZeneca; these relationships are regulated by Tufts University.
Supplementary Figures and Table
Supplementary Table 1 and Supplementary Figures 1–5 (PDF 1392 kb)
Rights and permissions
About this article
Cite this article
Cardarelli, R., Jones, K., Pisella, L. et al. The small molecule CLP257 does not modify activity of the K+–Cl− co-transporter KCC2 but does potentiate GABAA receptor activity. Nat Med 23, 1394–1396 (2017). https://doi.org/10.1038/nm.4442
This article is cited by
Molecular Mechanisms of Epilepsy: The Role of the Chloride Transporter KCC2
Journal of Molecular Neuroscience (2022)
The role of GABAergic signalling in neurodevelopmental disorders
Nature Reviews Neuroscience (2021)
Reply to The small molecule CLP257 does not modify activity of the K+–Cl− co-transporter KCC2 but does potentiate GABAA receptor activity
Nature Medicine (2017)